Omicron Breakthrough Infection After Heterologous Prime-Boost Vaccination Induces a Vigorous Antibody Response | Zendy

Augusto Varese | Zendy; Bianca Mazzitelli | Zendy; Fernando Erra Díaz | Zendy; María Victoria Kjolhede | Zendy; Diego Ojeda | Zendy; Alejandra Vellicce | Zendy; Penélope Arto | Zendy; Carla Y Cícero | Zendy; María Pascowsky | Zendy; Laura Figueras | Zendy; Bárbara Broese | Zendy; Rosa Dávila | Zendy; Rocío Zarlenga | Zendy; Federico Rivelli | Zendy; Camila Verruno | Zendy; Valeria Silenzi | Zendy; Ivana Beltrán | Zendy; Andrea V. Gamarnik | Zendy; Ana Ceballos | Zendy; Carlos Zala | Zendy; Adelina Badolati | Zendy; Jorge Geffner | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Omicron Breakthrough Infection After Heterologous Prime-Boost Vaccination Induces a Vigorous Antibody Response

Author(s) -

Augusto Varese,

Bianca Mazzitelli,

Fernando Erra Díaz,

María Victoria Kjolhede,

Diego Ojeda,

Alejandra Vellicce,

Penélope Arto,

Carla Y Cícero,

María Pascowsky,

Laura Figueras,

Bárbara Broese,

Rosa Dávila,

Rocío Zarlenga,

Federico Rivelli,

Camila Verruno,

Valeria Silenzi,

Ivana Beltrán,

Andrea V. Gamarnik,

Ana Ceballos,

Carlos Zala,

Adelina Badolati,

Jorge Geffner

Publication year - 2022

Publication title -

the journal of infectious diseases

Language(s) - Uncategorized

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1093/infdis/jiac250

Subject(s) - vaccination , asymptomatic , neutralizing antibody , antibody , heterologous , antibody response , virology , immunology , medicine , biology , pathology , biochemistry , gene

Infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant is usually asymptomatic or mild and appears to be poorly immunogenic at least in unvaccinated individuals. Here, we found that health care workers vaccinated with 2 doses of Sputnik V and a booster dose of ChAdOx1 mount a vigorous neutralizing-antibody response after Omicron breakthrough infection.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research